Search
Displaying results 2441 - 2450 of 10000 in total
Edralbrutinib
go.drugbank.com/drugs/DB18095InvestigationalEdralbrutinib is an orally available small molecule inhibitor of Bruton's tyrosine kinase.
Synonyms: 4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7h-pyrrolo(2,3-d)pyridazin-7-one, 7h-pyrrolo(2,3-d)pyridazin-7-one, 4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-TQS-168
go.drugbank.com/drugs/DB18108ExperimentalSynonyms: 2-(4-Tert-butylphenyl)-1H-benzimidazoleCategories: Heterocyclic Compounds, 2-Ring2'-deoxythioguanosine
go.drugbank.com/drugs/DB18117ExperimentalCategories: Heterocyclic Compounds, 2-RingSynonyms: 2-amino-9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-mercaptopurine, 2'-deoxy-6-thioguanosineEP-0042
go.drugbank.com/drugs/DB18120InvestigationalSynonyms: 3H-IMIDAZO(4,5-B)PYRIDINE, 6-CHLORO-7-(4-((4-CHLOROPHENYL)METHYL)-1-PIPERAZINYL)-2-(1,3-DIMETHYL-1H-PYRAZOL-4-YL)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFarabursen
go.drugbank.com/drugs/DB18127InvestigationalRGLS-8429 is an investigational anti-miR-17 oligonucleotide.
Briquilimab
go.drugbank.com/drugs/DB18136InvestigationalBriquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
Synonyms: IMMUNOGLOBULIN G1 (297-GLUTAMINE), ANTI-(HUMAN C-KIT RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .KAPPA.-CHAIN, DIMERATX-01
go.drugbank.com/drugs/DB18141InvestigationalATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
MTL-CEBPA
go.drugbank.com/drugs/DB18143InvestigationalMTL-CEBPA is a SMARTICLES liposomal formulation of MTL-501, a small activating RNA (saRNA) oligonucleotide.
ESK981
go.drugbank.com/drugs/DB18155InvestigationalSynonyms: 4h-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-, 4-methylbenzenesulfonate (1:1)Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBRG01
go.drugbank.com/drugs/DB18173InvestigationalBRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]